Table 1.

Proportion of patients (n [%]) on sirukumab with key lab abnormalities through Wk 24

Sirukumab dose	CTCAE grade	Global study – with MTX		Global study – no MTX

		50mg q4w	100mg q2w	50mg q4w	100mg q2w
		(n=562)	(n=564)	(n=86)	(n=85)

ALT increased	1	330 (58.7)	312 (55.3)	27 (31.4)	33 (38.8)
	2	32 (5.7)	46 (8.2)	2 (2.3)	5 (5.9)
	3	9 (1.6)	20 (3.5)	1 (1.2)	0
	4	0	0	0	0
AST increased	1	266 (47.3)	283 (50.2)	22 (25.6)	28 (32.9)
	2	15 (2.7)	20 (3.5)	2 (2.3)	1 (1.2)
	3	1 (0.2)	5 (0.9)	0	0
	4	0	0	0	0
Neutrophils decreased	1	104 (18.5)^a	113 (20.1)^b	17 (19.8)^c	15 (17.6)
	2	66 (11.8)^a	63 (11.2)^b	9 (10.5)^c	11 (12.9)
	3	20 (3.6)^a	13 (2.3)^b	2 (2.3)^c	3 (3.5)
	4	0	1 (0.2)^b	0	0